Physician profile
Maritza E Carrillo
NPI 1649628587
$4,059.17
in general payments reported to CMS, 2019-2025
17 companies · $541 in 2025
The $541 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $66.64 · 2021: $251 · 2022: $1,255 · 2023: $638 · 2024: $1,170 · 2025: $541.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,348.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $650.36 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Ascensia Diabetes Care US INC. | $587.36 | 2022-2025 | |
| Novo Nordisk INC | $513.61 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $409.50 | 2020-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $383.36 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $356.64 | 2022-2025 | Tepezza, Evenity, Prolia |
| Astrazeneca Pharmaceuticals Lp | $251.48 | 2019-2022 | |
| Abbott Laboratories | $223.11 | 2020-2025 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $177.59 | 2022-2023 | Tepezza |
| Insulet Corporation | $125.58 | 2022-2025 | Omnipod |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.18 | 2022 | |
| Mannkind Corporation | $107.22 | 2020-2024 | Afrezza |
| Amphastar Pharmaceuticals, INC. | $66.84 | 2024-2025 | |
| Tandem Diabetes Care, INC. | $46.88 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $25.00 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $14.34 | 2019 | |
| Merck Sharp & Dohme LLC | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maritza Carrillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.